Literature DB >> 7776301

Off-label drug prescribing on a state university obstetric service.

W F Rayburn1, G L Turnbull.   

Abstract

Off-label drug use occurs when physicians prescribe a drug recommended for indications other than those listed on the prescription labeling. The purpose of the present investigation was to describe patterns of off-label drug use during pregnancy, including the types of drugs and their timing of use. All study pregnancies had to receive prenatal care at our state university clinics before 14 weeks' gestation and deliver at our institution during a five-month period. Prenatal records were reviewed, and subjects were interviewed after delivery. A total of 165 (22.6%) of the 731 eligible subjects took > or = 1 (average 1.7, 95% confidence interval 1.3-3.8) drugs for off-label indications. Nearly all drugs were taken for a short term during the third trimester. The primary purposes were to avoid an obstetric complication (premature labor and delivery, preeclampsia/eclampsia) or improve the capacity for eventual postnatal adaptation. Despite discussions with patients, on no occasion was it recorded on the chart that the patient was informed that the drug was recommended for an off-label indication. Results from this study should help drug manufacturers, insurance companies and federal regulatory agencies understand the common use of recommending certain drugs for off-label indications during pregnancy.

Entities:  

Mesh:

Year:  1995        PMID: 7776301

Source DB:  PubMed          Journal:  J Reprod Med        ISSN: 0024-7758            Impact factor:   0.142


  9 in total

Review 1.  Off-label use of anti-cancer drugs between clinical practice and research: the Italian experience.

Authors:  Rosa Lerose; Pellegrino Musto; Michele Aieta; Carla Papa; Alfredo Tartarone
Journal:  Eur J Clin Pharmacol       Date:  2011-12-14       Impact factor: 2.953

2.  A pregnancy physiologically based pharmacokinetic (p-PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4.

Authors:  Lu Gaohua; Khaled Abduljalil; Masoud Jamei; Trevor N Johnson; Amin Rostami-Hodjegan
Journal:  Br J Clin Pharmacol       Date:  2012-11       Impact factor: 4.335

3.  Are incorrectly used drugs more frequently involved in adverse drug reactions? A prospective study.

Authors:  A P Jonville-Béra; F Béra; E Autret-Leca
Journal:  Eur J Clin Pharmacol       Date:  2005-04-12       Impact factor: 2.953

4.  Barriers to contraceptive use in product labeling and practice guidelines.

Authors:  Daniel Grossman; Charlotte Ellertson; Katrina Abuabara; Kelly Blanchard; Francisco T Rivas
Journal:  Am J Public Health       Date:  2006-01-31       Impact factor: 9.308

5.  Medication-Wide Association Study Using Electronic Health Record Data of Prescription Medication Exposure and Multifetal Pregnancies: Retrospective Study.

Authors:  Lena Davidson; Silvia P Canelón; Mary Regina Boland
Journal:  JMIR Med Inform       Date:  2022-06-07

6.  Off-label prescribing patterns of antiemetics in children: a multicenter study in Italy.

Authors:  Davide Zanon; Luca Gallelli; Francesca Rovere; Rossella Paparazzo; Natalia Maximova; Marzia Lazzerini; Antonio Reale; Tiziana Corsetti; Salvatore Renna; Tullia Emanueli; Francesco Mannelli; Francesco Manteghetti; Liviana Da Dalt; Caterina Palleria; Nicola Banchieri; Antonio Urbino; Mario Miglietta; Giovanni Cardoni; Adriana Pompilio; Alberto Arrighini; Clara Lazzari; Gianni Messi
Journal:  Eur J Pediatr       Date:  2012-12-04       Impact factor: 3.183

7.  Prediction of Maternal and Fetal Acyclovir, Emtricitabine, Lamivudine, and Metformin Concentrations during Pregnancy Using a Physiologically Based Pharmacokinetic Modeling Approach.

Authors:  Khaled Abduljalil; Amita Pansari; Jia Ning; Masoud Jamei
Journal:  Clin Pharmacokinet       Date:  2022-01-24       Impact factor: 6.447

8.  Lessons learned in pediatric clinical research to evaluate safe and effective use of drugs in pregnancy.

Authors:  Daniel Gonzalez; Kim A Boggess; Michael Cohen-Wolkowiez
Journal:  Obstet Gynecol       Date:  2015-04       Impact factor: 7.623

Review 9.  Preeclampsia - will orphan drug status facilitate innovative biological therapies?

Authors:  Sinuhe Hahn
Journal:  Front Surg       Date:  2015-02-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.